Get the Stockscreener App
98.83
10.71%
9.56
Pre-market:
99.86
1.03
+1.04%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $98.83, with a volume of 31.25M.
It is up +10.71% in the last 24 hours and up +9.06% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$89.27
Open:
$95.29
24h Volume:
31.25M
Relative Volume:
2.33
Market Cap:
$172.14B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
27.53
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+4.69%
1M Performance:
+9.06%
6M Performance:
-18.83%
1Y Performance:
-24.98%
1-Day Range:
$94.99
$101.87
1-Week Range:
$87.64
$101.87
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
98.83 | 172.14B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
331.20 | 126.97B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.56 | 106.96B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.62 | 66.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.84 | 50.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Raising Dividends for 54 Consecutive Years to Reward Shareholders, Abbott Laboratories’ Diversified Layout Consolidates Its Growth Foundation - NAI500
What Helped Abbott Laboratories (NYSE:ABT) Raise Full-Year Outlook? - Kalkine Media
Abbott Laboratories (ABT) Could Be 15% Undervalued On Raised 2026 Earnings Outlook - simplywall.st
Why Abbott Stock Jumped Today - Yahoo Finance
Abbott Is On Deck to Launch Several New Devices - Morningstar
Abbott Laboratories’s Stock Price Soars to $98.83, Enjoying a Robust 10.71% Uptick - Smartkarma
Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off - The Motley Fool
BTIG raises Abbott Labs stock price target to $134 on Q2 strength - Investing.com
Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Stro - GuruFocus
Abbott (ABT) Lifts 2026 EPS Outlook Amid Business Mix Shift Toward Devices and Diagnostics - Yahoo Finance
Abbott (ABT) Receives Outperform Rating Amid Positive Q2 Results - GuruFocus
Abbott Laboratories Stock Draws Fresh Targets As Growth Story Builds - StocksToTrade
Abbott Laboratories (ABT) Surges on Upbeat Q2 Earnings and Revis - GuruFocus
Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years - Barron's
How Abbott Laboratories (ABT) performed in Q2 2026 - AlphaStreet
Abbott Labs Draws Bullish Targets As Legal Overhang Fades - timothysykes.com
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
Abbott Laboratories (ABT) Shares Surge Over 10% After Strong Q2 Earnings - GuruFocus
Abbott Laboratories Draws Bullish Targets As Legal Overhang Eases - StocksToTrade
Strong Demand and Growth Forecast for Abbott Laboratories (ABT) - GuruFocus
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street - MarketBeat
Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise - marketscreener.com
Why Is Abbott Stock Skyrocketing Thursday?Abbott Laboratories (NYSE:ABT) - Benzinga
Abbott stock powers through 100-DMA, but long-term downtrend still looms (ABT:NYSE) - Seeking Alpha
Abbott (ABT) Shares Rise 10.7% - GuruFocus
Abbott Laboratories Draws Bullish Targets As Legal Overhang Fades - StocksToTrade
Abbott Q2 2026 earnings beat, raises full-year profit guidance - qz.com
Abbott Laboratories shares jump as earnings beat estimates and company raises 2026 outlook - Yahoo Finance
Abbott Labs beats Q2 estimates, raises 2026 out... - Pluang
Stocks making the biggest moves midday: Manpower, Abbott, UnitedHealth, TSMC & more - CNBC
Abbott reports $12.6 billion Q2 2026 sales - grafa.com
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market - Yahoo Finance
Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade) (ABT) - Seeking Alpha
Abbott (ABT) Raises Full-Year EPS Guidance Amid Strong Q2 Revenue Growth - GuruFocus
Abbott surges 12% on raised EPS outlook - Breakingthenews.net
Abbott Raised Its 2026 Outlook After A Solid Quarter - Finimize
Abbott Laboratories Q2 Earnings Call Highlights - Yahoo Finance
Abbott Laboratories Stock (ABT) Rallies on a Q2 Earnings Beat and a 2026 EPS Guidance Increase - TipRanks
Abbott (ABT) Sees Significant Stock Surge of 12.5% - GuruFocus
Earnings call transcript: Abbott beats Q2 2026 estimates and lifts outlook - Investing.com
Abbott (ABT) Sees Significant Gains in Morning Trading - GuruFocus
Abbott Stock Soars 13% On Earnings Beat, Guidance RaiseAbbott Laboratories (NYSE:ABT) - Benzinga
Abbott Laboratories Raises Full-Year Earnings Guidance as Second-Quarter Results Top Views - Moomoo
Abbott raises 2026 guidance after strong second quarter - Crain's Chicago Business
Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Abbott beats Q2 earnings, raises 2026 profit guidance - eciks.org
Abbott, Up 14%, Strikes Three-Month High After Boosting 2026 Profit Outlook - Investor's Business Daily
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Benzinga
Abbott shares rise 4% as Q2 earnings beat estimates, driven by strong diagnostics growth. - Pluang
Abbott Laboratories Stock Draws Bullish Targets Ahead Of Earnings - StocksToTrade
Why Abbott Stock Is Reimagining Its Future - Trefis
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):